跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DEPO-PROVERA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DEPO-PROVERA
Authorized
STANDARD
DEPO-PROVERA
Pfizer Canada Ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
b42b7533e3c3160b
Company
Pfizer Canada Ulc
Type
Standard
Approval Details
Approval Id
b42b7533e3c3160b
Drug Approval Canada Name
DEPO-PROVERA
Product Name
DEPO-PROVERA
Status
Marketed
Status Date
2022-04-25
Original Market Date
2022-04-25
Din
02523493
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
Prescription
Ahfs
68:12.00
Atc Original
G03AC06 MEDROXYPROGESTERONE
Atc Name
g 03 ac 06
Aig Number
0106339003
Company Name
Pfizer Canada Ulc
Company Address
17300 Trans-Canada Highway, Kirkland, Quebec, Canada, H9J 2M5
Company Detail Path
/organization/pfizer-canada-ulc
Company Information
Pharmaceutical Company Name
Pfizer Canada Ulc
Country Name
Canada
Province Name
Quebec
City Name
kirkland,quebec,country_ca
Address
17300 rte Transcanadienne
Active Ingredients
MEDROXYPROGESTERONE ACETATE
150 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
b42b7533e3c3160b
Type
Standard
Back to Health Canada Approvals